• Telix reports Q4 2024 unaudited revenue of US$142 million, a 46% increase over the prior year
• Full year FY2024 unaudited revenue of US$517 million, exceeding previous guidance
• Significant progress in therapeutics pipeline, including TLX591, TLX250, and TLX101

Telix Pharmaceuticals Limited has provided an update on its commercial and operational performance for the quarter ended 31 December 2024 (Q4 2024). The company reported unaudited revenue of approximately US$142 million (AU$218 million) for Q4 2024, representing a 46% increase over the prior year corresponding quarter (Q4 2023: US$97 million or AU$148 million) and a 5% quarter-over-quarter increase (Q3 2024: US$135 million or AU$201 million). Telix's revenue is currently generated predominantly from sales of its diagnostic radiopharmaceutical Illuccix for prostate cancer PET imaging. For the full year FY2024, Telix reported unaudited revenue of approximately US$517 million (AU$783 million), exceeding its previously stated guidance of US$490 million to US$510 million (AU$745 million to AU$776 million), representing a 55% increase over FY2023. The company's investment into research and development (R&D) remained in line with guidance, funded by earnings generated from product sales. Telix made significant progress in its therapeutics pipeline during Q4 2024, including advancing the registrational clinical trial for its lead therapeutic asset TLX591 (177Lu-rosapatamab) for prostate cancer, obtaining a pre-IND meeting with the FDA for its kidney cancer therapy candidate TLX250 (177Lu-girentuximab), and holding a pre-IND meeting with the FDA to discuss the design of a pivotal trial for its glioblastoma therapy candidate TLX101 (131I-iodofalan, or 131I-IPA). The company also entered into agreements to acquire a suite of clinically validated assets targeting fibroblast activation protein (FAP), a promising pan-cancer target, and announced the acquisition of a groundbreaking platform technology and drug discovery capability from ImaginAb Inc. In the precision medicine business, Telix submitted a Biologics License Application (BLA) for its renal cancer imaging candidate TLX250-CDx (Zircaix®, 89Zr-girentuximab) and had its New Drug Application (NDA) for brain cancer imaging candidate TLX101-CDx (Pixclara®, 18F-floretyrosine or 18F-FET) accepted by the FDA with a Priority Review. The company also provided updates on the regulatory status of its Illuccix product in various markets, including the EU, UK, and Brazil. Additionally, Telix announced a partnership with Subtle Medical for AI-powered PET imaging with Illuccix and an agreement with Curium Pharma for the transfer of marketing and distribution rights for its infection imaging product Scintimun®. The company also made progress in its manufacturing capabilities, including the acquisition of RLS (USA) Inc and the completion of the installation of two new cyclotrons at its facility in Brussels South, Belgium.

Telix reported unaudited FY2024 revenue of approximately US$517 million, exceeding its previously stated guidance of US$490 million to US$510 million. The company intends to provide FY2025 guidance when it reports audited FY2024 annual results on 20 February 2025.

Telix is well-positioned for significant expansion, including planned launches of multiple imaging products in key markets and advancing late-stage therapeutic assets into pivotal trials. 2025 is shaping up to be a transformative year for the company.